Publications

Gabitova-Cornell L, Surumbayeva A, Peri S, Franco-Barraza J, Restifo D, Weitz N, Ogier C, Goldman AR, Hartman TR, Francescone R, Tan Y, Nicolas E, Shah N, Handorf EA, Cai KQ, O'Reilly AM, Sloma I, Chiaverelli R, Moffitt RA, Khazak V, Fang CY, Golemis EA, Cukierman E, Astsaturov I. 2020. Cholesterol Pathway Inhibition Induces TGF-? Signaling to Promote Basal Differentiation in Pancreatic Cancer. Cancer Cell 38(4):567-583. e11. doi: 10.1016/j.ccell.2020.08.015. Epub 2020 Sep 24.PMID: 32976774

Makhov P, Sohn JA, Serebriiskii IG, Fazliyeva R, Khazak V, Boumber Y, Uzzo RG, Kolenko VM. 2020. CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinoma. Br J Cancer Sep 24. doi: 10.1038/s41416-020-01087-x. Online ahead of print.

Gaponova AV, Nikonova AS, Deneka A, Kopp MC, Kudinov AE, Skobeleva N, Khazak V, Ogawa LS, Cai KQ, Duncan KE, Duncan JS, Egleston BL, Proia DA, Boumber Y, Golemis EA. A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer. Clin Cancer Res. 2016 Oct 15;22(20):5120-5129. doi: 10.1158/1078-0432.CCR-15-3068.

Beeharry N, Banina E, Hittle J, Skobeleva N, Khazak V, Deacon S, Andrake M, Egleston BL, Peterson JR, Astsaturov I, Yen TJ. 2014. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints. Cell Cycle;13(14):2172-91. doi: 10.4161/cc.29214

Khazak V, Eyrisch S, Kato J, Tamanoi F, Golemis EA. 2013. A two-hybrid approach to identify inhibitors of the RAS-RAF interaction. Enzymes. 2013;33 Pt A:213-48. doi: 10.1016/B978-0-12-416749-0.00010-5.

González-Pérez V, Reiner DJ, Alan JK, Mitchell C, Edwards LJ, Khazak V, Der CJ, Cox AD. 2010. Genetic and functional characterization of putative Ras/Raf interaction inhibitors in C. elegans and mammalian cells. J Mol Signal;5:2. doi: 10.1186/1750-2187-5-2.

Campbell PM, Lee KM, Ouellette MM, Kim HJ, Groehler AL, Khazak V, Der CJ. 2008. Ras-driven transformation of human nestin-positive pancreatic epithelial cells. Methods Enzymol;439:451-65. doi: 10.1016/S0076-6879(07)00431-4.

Rothweiler U, Czarna A, Krajewski M, Ciombor J, Kalinski C, Khazak V, Ross G, Skobeleva N, Weber L, Holak TA. Isoquinolin-1-one inhibitors of the MDM2-p53 interaction. ChemMedChem. 2008 Jul;3(7):1118-28. doi: 10.1002/cmdc.200800025.

Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA. 2007. Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets;11(12):1587-609. Review. Erratum in: Expert Opin Ther Targets. 2009 Sep;13(9):1135.

Hao H, Muniz-Medina VM, Mehta H, Thomas NE, Khazak V, Der CJ, Shields JM. 2007. Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth. Mol Cancer Ther;6(8):2220-9.

Popowicz GM, Czarna A, Rothweiler U, Szwagierczak A, Krajewski M, Weber L, Holak TA. 2007. Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle;6(19):2386-92.

Skobeleva N, Menon S, Weber L, Golemis EA, Khazak V. 2007. In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors. Mol Cancer Ther;6(3):898-906.

Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V, Der CJ. 2007. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res;67(5):2098-106.

Khazak V, Golemis EA, Weber L. 2005. Development of a yeast two-hybrid screen for selection of human Ras-Raf protein interaction inhibitors. Methods Mol Biol. 310:253-71.

Weber L. Chemistry for chemical genomics. Methods Mol Biol. 2005;310:11-24.

Lu Y, Sakamuri S, Chen QZ, Keng YF, Khazak V, Illgen K, Schabbert S, Weber L, Menon SR. Solution phase parallel synthesis and evaluation of MAPK inhibitory activities of close structural analogues of a Ras pathway modulator. Bioorg Med Chem Lett. 2004 Aug 2;14(15):3957-62.

Kato-Stankiewicz J, Hakimi I, Zhi G, Zhang J, Serebriiskii I, Guo L, Edamatsu H, Koide H, Menon S, Eckl R, Sakamuri S, Lu Y, Chen QZ, Agarwal S, Baumbach WR, Golemis EA, Tamanoi F, Khazak V. Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14398-403.

Tarpinian S, Rowe J, Husanov R, Saha U, Banerjee P, Eraslan R, Jones B, Festin S, Khazak V. Invivotek, Hamilton, NJ. NexusPharma, Philadelphia, PA. Charles River Laboratories Research Models and Services (RMS), Wilmington, MA. Assessment of sensitivity to a PD-1 check point inhibitor and cisplatin in bladder cancer patient-derived xenografts with various levels of PD-L1 expression in HuCD34NCG mice. Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020); November 9-14, 2020; Virtual.

Krais J, Clausen E, Khazak V, Astsaturov I, Scott CL, Johnson N. Assessment of PARPi and cisplatin resistance in BRCA1 exon 11 mutant patient-derived xenografts. American Association for Cancer Research (AACR) Special Conference on Advances in Ovarian Cancer Research; September 13-16, 2019; Atlanta, GA.